EP0997148A1 — Phosphate-binding polymer preparations
Assigned to Chugai Pharmaceutical Co Ltd · Expires 2000-05-03 · 26y expired
What this patent protects
Tablets which contain phosphate-binding polymers having an average particle size of 400 µm or less, containing particles of 500 µm or less in particle size at a ratio of at least 90 % and showing a moisture content of 1 to 14 % and crystalline cellulose and/or hydroxypropylcellul…
USPTO Abstract
Tablets which contain phosphate-binding polymers having an average particle size of 400 µm or less, containing particles of 500 µm or less in particle size at a ratio of at least 90 % and showing a moisture content of 1 to 14 % and crystalline cellulose and/or hydroxypropylcellulose with a low degree of substitution; and a process for producing the same. These tablets have a high active component content and an excellent ability to bind to phosphates and are quickly disintegrated in an acidic to neutral region while being little affected by stirring strength. Thus, they are excellent preparations capable of lessening changes in bioavailability depending on pH value.
Drugs covered by this patent
- Renvela (SEVELAMER CARBONATE) · Sanofi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.